[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650802":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":65,"collaborators":43,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":43,"enrollmentInfo":77,"targetDuration":43,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":43,"overallStatus":50,"whyStopped":43,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Edoxaban-based treatment group","EXPERIMENTAL","Edoxaban 60mg once daily orally, continue until follow-up is complete.",[13],"Drug: Edoxaban",{"label":15,"type":16,"description":17,"interventionNames":18},"Apixaban-based treatment group","ACTIVE_COMPARATOR","Apixaban 5mg twice a day orally, continue until follow-up is complete.",[19],"Drug: Apixaban",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Edoxaban","Edoxaban 60mg will be administered once daily orally according to the study protocol.",[9],[27],"Lixiana",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Apixaban","Apixaban 5mg will be administered twice a day orally according to the study protocol.",[15],[33],"Eliquis",[35],{"name":36,"affiliation":5,"role":37},"Joo-yong Hahn, MD, PhD","PRINCIPAL_INVESTIGATOR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Joo-Yong Hahn, MD, PhD","CONTACT","82-2-3410-6653",null,"Jooyong.hahn@gmail.com",{"name":46,"role":41,"phone":42,"phoneExt":43,"email":47},"Ki-Hong Choi, MD, PhD","cardiokh@gmail.com",[49],{"facility":5,"status":50,"city":51,"state":43,"zip":52,"country":53,"countryCode":43,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Seoul","06351","South Korea",{"type":55,"coordinates":56},"Point",[57,58],126.9784,37.566,{"lat":58,"lon":57},[61],{"name":62,"role":41,"phone":63,"phoneExt":43,"email":64},"Jooyong Hahn","+82 02-3410-6653","mijin.eom@sbri.co.kr",{"type":37,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Joo-Yong Hahn","Professor","100650802","net-clinical-benefit-of-edoxaban-versus-apixaban-in-patients-with-atrial-fibrillation-and-coronary-artery-disease-100650802",false,"NCT07753200","Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease","SMARTDECISION3","Inclusion Criteria:\n\n* Patients must be at least 19 years of age\n* Patients with AF requiring oral anticoagulation therapy (CHA2DS2-VaSc 2 or more)\n* Documented coronary artery disease, defined as at least one of the following: history of percutaneous coronary intervention (PCI), history of coronary artery bypass grafting (CABG), major epicardial coronary artery stenosis ≥50% on coronary computed tomography angiography (CCTA) or invasive coronary angiography\n* Patients who can understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindications to study medications (apixaban or edoxaban)\n* Severe renal impairment (creatinine clearance \\\u003C15 mL\u002Fmin) or dialysis\n* Active major bleeding\n* Indication requiring alternative anticoagulation (e.g., mechanical valve surgery or moderate \u002F severe mitral stenosis)\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Pregnant or lactating women","ALL","19 Years",{"count":78,"type":79},3000,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF). However, evidence comparing edoxaban and apixaban remains limited in AF patients with coexisting coronary artery disease(CAD). This study aims to evaluate whether edoxaban-based therapy is non-interior to apixaban-based therapy with respect to Net Adverse Clinical Events(NACE) in AF patients with concomitant CAD.",[85,86],"Atrial Fibrillation (AF)","Coronary Arterial Disease (CAD)","2026-08-06",{"date":89,"type":90},"2026-08-10","ACTUAL",{"date":92,"type":90},"2026-07-20",{"date":94,"type":79},"2031-12-31",{"name":5,"class":6},1]